This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
GANG ZHI ZHANG
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The transcriptional co-activator with PDZ-binding motif(TAZ) and Yes-associated protein(YAP) are well-known members of the Hippo signaling pathway, which may correlated with organ development regulation and interaction between organ and tumor. At the same time, it is closely related to the occurrence and development of tumors.
Methods: The purpose of this study is to explore a potential marker that is specific for gastric cancer. In our study, we designed a bioinformatics analysis of the clinicopathological features of TAZ and YAP mRNA expression in gastric cancer using Kaplan-Meier plotter, Oncomine and TCGA databases.
Results: According to Kaplan-Meier plotter, the mRNA expression of TAZ and YAP are negatively related with the overall post-progression and first progression survival rates of gastric cancer patients(p＜0.05), even stratified by clinicopathological features(p＜0.05). As shown in Oncomine, TAZ and YAP mRNA expression is higher in gastric cancers than gastric tissue and gastric mucosa(p＜0.05). In TCGA data, univariate analysis showed that age, TNM staging, lymph node metastasis, distant metastasis was correlated with prognosis in patients with gastric cancer(p＜0.05). COX multivariate analysis showed that age and distant metastasis are risk factors affecting the survival of patients with gastric cancer(p＜0.05).
Conclusion: TAZ/YAP may be employed as a good molecular market for patients and might help researchers discover a targeted inhibitor for treating gastric cancer.
Keywords
TAZ, YAP, gastric cancer, bioinformatics analysis, clinicopathological features
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Mar, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
GANG ZHI ZHANG
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Mar, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The transcriptional co-activator with PDZ-binding motif(TAZ) and Yes-associated protein(YAP) are well-known members of the Hippo signaling pathway, which may correlated with organ development regulation and interaction between organ and tumor. At the same time, it is closely related to the occurrence and development of tumors.
Methods: The purpose of this study is to explore a potential marker that is specific for gastric cancer. In our study, we designed a bioinformatics analysis of the clinicopathological features of TAZ and YAP mRNA expression in gastric cancer using Kaplan-Meier plotter, Oncomine and TCGA databases.
Results: According to Kaplan-Meier plotter, the mRNA expression of TAZ and YAP are negatively related with the overall post-progression and first progression survival rates of gastric cancer patients(p＜0.05), even stratified by clinicopathological features(p＜0.05). As shown in Oncomine, TAZ and YAP mRNA expression is higher in gastric cancers than gastric tissue and gastric mucosa(p＜0.05). In TCGA data, univariate analysis showed that age, TNM staging, lymph node metastasis, distant metastasis was correlated with prognosis in patients with gastric cancer(p＜0.05). COX multivariate analysis showed that age and distant metastasis are risk factors affecting the survival of patients with gastric cancer(p＜0.05).
Conclusion: TAZ/YAP may be employed as a good molecular market for patients and might help researchers discover a targeted inhibitor for treating gastric cancer.
Figure 1
Figure 2
Loading...